<p>Neoadjuvant chemotherapy (NAC) for breast cancer is widely employed. We performed genome-wide association studies (GWAS) to determine if germline genetic variability was associated with benefits, in terms of pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS), in patients entered on the NSABP B-40 NAC (National Surgical Adjuvant Breast and Bowel Project, B-40, Neoadjuvant Chemotherapy) trial where some patients were randomized to receive bevacizumab, in addition to chemotherapy. </p>

Neoadjuvant Chemotherapy +/- Bevacizumab Pharmacogenomics

Breast Neoplasms study with SNP Genotypes (Array) data on dbGaP (920 participants)

Neoadjuvant Chemotherapy +/- Bevacizumab Pharmacogenomics

Description

Applying For Access

Summary